- Home
- FTHM vs MAIA Comparison
FTHM vs MAIA Comparison
Compare FTHM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- MAIA
- Stock Information
- Founded
- FTHM 2010
- MAIA 2018
- Country
- FTHM United States
- MAIA United States
- Employees
- FTHM N/A
- MAIA N/A
- Industry
- FTHM Real Estate
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- MAIA Health Care
- Exchange
- FTHM Nasdaq
- MAIA Nasdaq
- Market Cap
- FTHM 54.7M
- MAIA 44.9M
- IPO Year
- FTHM 2020
- MAIA 2022
- Fundamental
- Price
- FTHM $1.25
- MAIA $1.11
- Analyst Decision
- FTHM Strong Buy
- MAIA
- Analyst Count
- FTHM 1
- MAIA 0
- Target Price
- FTHM $2.50
- MAIA N/A
- AVG Volume (30 Days)
- FTHM 209.8K
- MAIA 742.2K
- Earning Date
- FTHM 11-11-2025
- MAIA 11-07-2025
- Dividend Yield
- FTHM N/A
- MAIA N/A
- EPS Growth
- FTHM N/A
- MAIA N/A
- EPS
- FTHM N/A
- MAIA N/A
- Revenue
- FTHM $390,032,000.00
- MAIA N/A
- Revenue This Year
- FTHM $25.22
- MAIA N/A
- Revenue Next Year
- FTHM $16.19
- MAIA N/A
- P/E Ratio
- FTHM N/A
- MAIA N/A
- Revenue Growth
- FTHM 19.16
- MAIA N/A
- 52 Week Low
- FTHM $0.65
- MAIA $1.05
- 52 Week High
- FTHM $3.37
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- FTHM 34.87
- MAIA 34.52
- Support Level
- FTHM $1.54
- MAIA $1.05
- Resistance Level
- FTHM $1.84
- MAIA $1.35
- Average True Range (ATR)
- FTHM 0.13
- MAIA 0.10
- MACD
- FTHM -0.03
- MAIA -0.03
- Stochastic Oscillator
- FTHM 15.94
- MAIA 12.85
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.